Compare AVNS & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVNS | WGS |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Industrial Specialties | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2014 | N/A |
| Metric | AVNS | WGS |
|---|---|---|
| Price | $25.10 | $51.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $120.71 |
| AVG Volume (30 Days) | 1.0M | ★ 2.1M |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.59 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $701,200,000.00 | N/A |
| Revenue This Year | $3.28 | $29.98 |
| Revenue Next Year | $4.23 | $25.92 |
| P/E Ratio | ★ $225.50 | $1,251.58 |
| Revenue Growth | ★ 1.95 | N/A |
| 52 Week Low | $9.30 | $32.21 |
| 52 Week High | $24.91 | $170.87 |
| Indicator | AVNS | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 86.18 | 52.19 |
| Support Level | $24.60 | $32.21 |
| Resistance Level | N/A | $73.46 |
| Average True Range (ATR) | 0.11 | 3.49 |
| MACD | -0.26 | 2.02 |
| Stochastic Oscillator | 59.57 | 93.69 |
Avanos Medical Inc is a medical technology company engaged in the development and commercialization of products for pain management and patient care. The company has two reportable segments: Specialty Nutrition Systems and Pain Management and Recovery. The Specialty Nutrition Systems segment provides enteral feeding and neonatal products. The Pain Management and Recovery segment offers surgical pain and recovery products, including pain pumps and radiofrequency ablation solutions for the treatment of chronic pain.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.